Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma
4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat...
Saved in:
| Published in | Biomolecules & therapeutics Vol. 26; no. 6; pp. 539 - 545 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.11.2018
한국응용약물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1976-9148 2005-4483 |
| DOI | 10.4062/biomolther.2018.006 |
Cover
| Abstract | 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model.
, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy. |
|---|---|
| AbstractList | 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model.
, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy. 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model. In vitro, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy. KCI Citation Count: 11 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model. In vitro, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy.4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model. In vitro, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy. 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome proliferator-activated receptor (PPAR) γ agonistic and anti-inflammatory effects. This study aimed to investigate the effect of PD1 on allergic asthma using rat basophilic leukemia (RBL)-2H3 mast cells and an ovalbumin (OVA)-induced asthma mouse model. In vitro, PD1 suppressed β-hexosaminidase activity in RBL-2H3 cells. In the OVA-induced allergic asthma mouse model, increased inflammatory cells and elevated Th2 and Th1 cytokine levels were observed in bronchoalveolar lavage fluid (BALF) and lung tissue. PD1 administration decreased the numbers of inflammatory cells, especially eosinophils, and reduced the mRNA and protein levels of the Th2 cytokines including interleukin (IL)-4 and IL-13, in BALF and lung tissue. The severity of inflammation and mucin secretion in the lungs of PD1-treated mice was also less. These findings indicate that PD1 could be a potential compound for anti-allergic therapy. |
| Author | Lee, Bo-Kyung Huang, Jin Jung, Jee H. Su, Mingzhi Im, Dong-Soon Kim, Mee-Jeong |
| Author_xml | – sequence: 1 givenname: Jin surname: Huang fullname: Huang, Jin organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea – sequence: 2 givenname: Mingzhi surname: Su fullname: Su, Mingzhi organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea – sequence: 3 givenname: Bo-Kyung surname: Lee fullname: Lee, Bo-Kyung organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea – sequence: 4 givenname: Mee-Jeong surname: Kim fullname: Kim, Mee-Jeong organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea – sequence: 5 givenname: Jee H. surname: Jung fullname: Jung, Jee H. organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea – sequence: 6 givenname: Dong-Soon surname: Im fullname: Im, Dong-Soon organization: Molecular Inflammation Research Center for Aging Intervention (MRCA) and College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29665659$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002400163$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kUtr3DAUhUVJaCZpf0GheJlANdXDlqxNYUjTZiAQaNO1kGUpViNLjmQPnX9fZyaPtouuLpf7nXOEzjE4CDEYAN5htCwRIx8bF_vox86kJUG4XiLEXoEFQaiCZVnTA7DAgjMocFkfgeOcf84AxxV7DY6IYKxilViA--_TMCSTs9uY4sJao8ci2qKEl9s2xV9bSODp8zJ0Jpix2_qzYp2jC230LhiIP1D42c2PK2IorjfKN1PvAlyHdtKmLVbem3TrdLHKY9erN-DQKp_N28d5An58ubg5v4RX11_X56srqKkoR8gpFxW2jJVC1NSaFjPaooYroxsrCEaaG0RKIqyuW6E1J6pt6to2tUIUa0RPwNneNyQr77STUbndvI3yLsnVt5u1pJwzQfnMftqzw9T0ptUmjEl5OSTXq7TdKf--BNfNPhvJSFWyncHpo0GK95PJo-xd1sZ7FUycsiSIcMSE4GJG3_-Z9Rzy1MkMiD2gU8w5GSu1G9U4f_Ac7bzESD70L1_6lw_9y7neWUv_0T7Z_0_1G6E6uKo |
| CitedBy_id | crossref_primary_10_3390_ijms23095270 crossref_primary_10_1016_j_intimp_2023_110995 crossref_primary_10_4062_biomolther_2020_176 crossref_primary_10_4062_biomolther_2022_024 crossref_primary_10_1007_s00011_025_02022_7 crossref_primary_10_4062_biomolther_2020_050 crossref_primary_10_1155_2020_8906968 crossref_primary_10_1124_jpet_120_264960 crossref_primary_10_1155_2021_7902592 crossref_primary_10_4062_biomolther_2019_160 crossref_primary_10_1080_17568919_2024_2437979 crossref_primary_10_4062_biomolther_2020_206 crossref_primary_10_3390_md19110586 |
| Cites_doi | 10.1016/j.jep.2013.05.037 10.1111/j.1600-065X.1988.tb00739.x 10.1016/j.pharmthera.2011.02.001 10.3390/md15010007 10.1016/j.coph.2012.06.001 10.1016/j.intimp.2004.10.017 10.1016/j.mce.2016.01.004 10.2337/diabetes.47.4.507 10.3390/md12020926 10.1016/j.jep.2017.11.018 10.1146/annurev.iy.12.040194.001303 10.1016/S0968-0896(02)00152-9 10.1371/journal.pone.0079985 10.1172/JCI16440 10.1016/j.jaci.2013.02.016 10.1016/j.aller.2012.07.018 10.1016/S0091-6749(97)70186-6 10.1038/383787a0 10.1155/2014/712962 10.1146/annurev.immunol.22.012703.104716 10.1165/ajrcmb.16.3.9070618 10.1046/j.1365-2222.2000.00772.x 10.4103/2231-4040.90879 10.4062/biomolther.2016.071 10.1164/ajrccm/147.2.291 10.1038/nm.3159 10.1371/journal.pone.0123094 10.1016/j.cellimm.2017.10.005 10.1034/j.1600-065X.2001.790117.x 10.4049/jimmunol.172.11.7053 10.1124/jpet.107.123265 10.1038/34178 10.1248/bpb.33.1028 10.3390/md14060112 10.1621/nrs.08004 10.2174/138955710791572442 10.1038/ni0802-715 10.1016/j.pharmthera.2017.08.011 10.1186/s13020-016-0094-9 10.1021/acs.jmedchem.5b00934 10.1016/j.cellsig.2017.08.003 |
| ContentType | Journal Article |
| Copyright | Copyright ©2018, The Korean Society of Applied Pharmacology 2018 |
| Copyright_xml | – notice: Copyright ©2018, The Korean Society of Applied Pharmacology 2018 |
| DBID | AAYXX CITATION NPM 7X8 5PM ACYCR |
| DOI | 10.4062/biomolther.2018.006 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2005-4483 |
| EndPage | 545 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_3776937 PMC6254637 29665659 10_4062_biomolther_2018_006 |
| Genre | Journal Article |
| GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM .UV NPM 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c394t-737951f6649983fed163d0b7aecbf9210c7e02429fc8d9cc72adb88fb8a031c03 |
| IEDL.DBID | M48 |
| ISSN | 1976-9148 |
| IngestDate | Tue Nov 21 21:41:51 EST 2023 Tue Sep 30 16:51:52 EDT 2025 Thu Oct 02 09:46:42 EDT 2025 Wed Feb 19 02:44:36 EST 2025 Tue Jul 01 04:15:28 EDT 2025 Thu Apr 24 23:06:52 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Ovalbumin Anti-asthma Anti-allergic PD1 RBL-2H3 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c394t-737951f6649983fed163d0b7aecbf9210c7e02429fc8d9cc72adb88fb8a031c03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2018.006 |
| PMID | 29665659 |
| PQID | 2027069979 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_3776937 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6254637 proquest_miscellaneous_2027069979 pubmed_primary_29665659 crossref_citationtrail_10_4062_biomolther_2018_006 crossref_primary_10_4062_biomolther_2018_006 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-11-01 |
| PublicationDateYYYYMMDD | 2018-11-01 |
| PublicationDate_xml | – month: 11 year: 2018 text: 2018-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Biomolecules & therapeutics |
| PublicationTitleAlternate | Biomol Ther (Seoul) |
| PublicationYear | 2018 |
| Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
| Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
| References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref39 ref16 ref38 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref42 ref41 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 |
| References_xml | – ident: ref27 doi: 10.1016/j.jep.2013.05.037 – ident: ref12 doi: 10.1111/j.1600-065X.1988.tb00739.x – ident: ref19 doi: 10.1016/j.pharmthera.2011.02.001 – ident: ref36 doi: 10.3390/md15010007 – ident: ref20 doi: 10.1016/j.coph.2012.06.001 – ident: ref3 doi: 10.1016/j.intimp.2004.10.017 – ident: ref9 doi: 10.1016/j.mce.2016.01.004 – ident: ref35 doi: 10.2337/diabetes.47.4.507 – ident: ref42 doi: 10.3390/md12020926 – ident: ref25 doi: 10.1016/j.jep.2017.11.018 – ident: ref33 doi: 10.1146/annurev.iy.12.040194.001303 – ident: ref28 doi: 10.1016/S0968-0896(02)00152-9 – ident: ref5 doi: 10.1371/journal.pone.0079985 – ident: ref23 doi: 10.1172/JCI16440 – ident: ref29 doi: 10.1016/j.jaci.2013.02.016 – ident: ref4 doi: 10.1016/j.aller.2012.07.018 – ident: ref40 doi: 10.1016/S0091-6749(97)70186-6 – ident: ref1 doi: 10.1038/383787a0 – ident: ref6 doi: 10.1155/2014/712962 – ident: ref13 doi: 10.1146/annurev.immunol.22.012703.104716 – ident: ref21 doi: 10.1165/ajrcmb.16.3.9070618 – ident: ref38 doi: 10.1046/j.1365-2222.2000.00772.x – ident: ref39 doi: 10.4103/2231-4040.90879 – ident: ref24 doi: 10.4062/biomolther.2016.071 – ident: ref11 doi: 10.1164/ajrccm/147.2.291 – ident: ref2 doi: 10.1038/nm.3159 – ident: ref26 doi: 10.1371/journal.pone.0123094 – ident: ref10 doi: 10.1016/j.cellimm.2017.10.005 – ident: ref18 doi: 10.1034/j.1600-065X.2001.790117.x – ident: ref16 doi: 10.4049/jimmunol.172.11.7053 – ident: ref15 doi: 10.1124/jpet.107.123265 – ident: ref32 doi: 10.1038/34178 – ident: ref7 doi: 10.1248/bpb.33.1028 – ident: ref17 doi: 10.3390/md14060112 – ident: ref30 doi: 10.1621/nrs.08004 – ident: ref34 doi: 10.2174/138955710791572442 – ident: ref41 doi: 10.1038/ni0802-715 – ident: ref31 doi: 10.1016/j.pharmthera.2017.08.011 – ident: ref37 doi: 10.1186/s13020-016-0094-9 – ident: ref8 doi: 10.1021/acs.jmedchem.5b00934 – ident: ref22 doi: 10.1016/j.cellsig.2017.08.003 – ident: ref14 |
| SSID | ssj0067156 |
| Score | 2.182156 |
| Snippet | 4-Hydroxy-2-(4-hydroxyphenethyl)isoindoline-1,3-dione (PD1) is a synthetic phthalimide derivative of a marine compound. PD1 has peroxisome... |
| SourceID | nrf pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 539 |
| SubjectTerms | Original 약학 |
| Title | Suppressive Effect of 4-Hydroxy-2-(4-Hydroxyphenethyl) Isoindoline-1,3-Dione on Ovalbumin-Induced Allergic Asthma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29665659 https://www.proquest.com/docview/2027069979 https://pubmed.ncbi.nlm.nih.gov/PMC6254637 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002400163 |
| Volume | 26 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomolecules & Therapeutics, 2018, 26(6), , pp.539-545 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2005-4483 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: KQ8 dateStart: 20120101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2005-4483 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 2005-4483 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: 5-W dateStart: 20130101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2005-4483 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2005-4483 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: M48 dateStart: 20120101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELZ4XHqpQNB2eckgVLUSptnEG8cntIKiBYn20pW4WX7CiiVhHyD498wk2dCtKOKSKIoTJ_lszzfxeD5C9rnxUoDrw3jsOANGrJmJI8sirTvCZQE2uHb44lfa6_Pzy87lApkFZNYfcPKqa4d6Uv3x8PBx9HQEHR746yGYo_gHLlQvhsiXMFQLYyPTr3cjhspSOANby2wskmWwXhLlHS54M9OQinap8NoGswwdn2dVZqL_3XfOei3m4_AaMf03vvIvg3W6Qj7WTJN2q6axShZ8vkZGqOJZhr4-eFplLqZFoJz1nhwGtLCYfWsOMPzLA5DD7_RsUoDzjgI_nrUPEnaCCY5okdPfD2WA8yBnKAJivaNdXFwI4yntTqbXt3qd9E9__jnusVp1gdlE8ikTiQDWFdIUfKEsCd4BY3OREdpbEyR4iFZ4NOwy2MxJa0WsncmyYDINA4SNkk9kKYdn-EIocEEXe251BCTTmAgKBZ6lXnDfcZzrFolnX1PZOiU5KmMMFbgmCIF6gUAhBAogaJGD5qK7KiPH28X3ACZ1YwcKM2nj_qpQN2MF_sKZSgRqQYoW2Z2hqKB74ZyJzn1xP1H4byhKpRSyRT5XqDa1xuAqAh-GM2IO76YAVjh_Jh9clym801KGQGy8o95N8gHfpVr_uEWWpuN7vw1EaGp2ypb8DCBKC54 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Suppressive+Effect+of+4-Hydroxy-2-%284-Hydroxyphenethyl%29+Isoindoline-1%2C3-Dione+on+Ovalbumin-Induced+Allergic+Asthma&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Huang%2C+Jin&rft.au=Su%2C+Mingzhi&rft.au=Lee%2C+Bo-Kyung&rft.au=Kim%2C+Mee-Jeong&rft.date=2018-11-01&rft.issn=1976-9148&rft.volume=26&rft.issue=6&rft.spage=539&rft_id=info:doi/10.4062%2Fbiomolther.2018.006&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-9148&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-9148&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-9148&client=summon |